Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report)’s share price gapped up before the market opened on Wednesday after HC Wainwright raised their price target on the stock from $28.00 to $33.00. The stock had previously closed at $10.45, but opened at $10.82. HC Wainwright currently has a buy rating on the stock. Cullinan Therapeutics shares last traded at $10.94, with a volume of 36,936 shares.
Separately, UBS Group assumed coverage on Cullinan Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $30.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $32.50.
Read Our Latest Research Report on Cullinan Therapeutics
Insider Activity at Cullinan Therapeutics
Institutional Investors Weigh In On Cullinan Therapeutics
Large investors have recently added to or reduced their stakes in the stock. Amalgamated Bank grew its position in shares of Cullinan Therapeutics by 97.3% during the third quarter. Amalgamated Bank now owns 1,768 shares of the company’s stock worth $30,000 after acquiring an additional 872 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Cullinan Therapeutics in the 4th quarter worth about $136,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Cullinan Therapeutics by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,346 shares of the company’s stock valued at $150,000 after purchasing an additional 1,195 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Cullinan Therapeutics during the second quarter valued at approximately $186,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Cullinan Therapeutics by 40.7% during the second quarter. The Manufacturers Life Insurance Company now owns 15,175 shares of the company’s stock worth $265,000 after buying an additional 4,393 shares during the period. 86.31% of the stock is owned by institutional investors and hedge funds.
Cullinan Therapeutics Stock Performance
The business has a fifty day moving average of $11.74 and a 200-day moving average of $15.24. The firm has a market capitalization of $639.37 million, a P/E ratio of -3.87 and a beta of -0.14.
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.09. On average, equities research analysts forecast that Cullinan Therapeutics, Inc. will post -3.12 earnings per share for the current fiscal year.
Cullinan Therapeutics Company Profile
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
See Also
- Five stocks we like better than Cullinan Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- High Flyers: 3 Natural Gas Stocks for March 2022
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Why is the Ex-Dividend Date Significant to Investors?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.